Of 14 patients available for six-month followup after cessation of natalizumab therapy, all but one had decreased counts in each of these lymphocyte populations; the one exception being a patient having a modest elevation in CD4+ and CD8+ T cell counts coincident with a clinical MS replase (19). This evidence concerns the gene CD8A and myeloid sarcoma.